In the first wave of this report, we examined how hemophilia is currently being treated and the impact that long acting therapies,Biogen Idec's ELOCTATE and ALPROLIX specifically, will have on the US market.
Our research indicates that Biogen Idec’s new therapies will play a significant role in the hemophilia A market. Physicians who treat hemophilia see the value that a reduced dosing frequency will have on patients’ quality of life and on treatment compliance.
We interviewed over 150 US-based, hemophilia-treating physicians in June and July of 2013 for this report. Subsequent waves of this report will explore the evolving perception and use of these new therapies, and other key events in the hemophilia market.
Download the report preview to learn more.